Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

LEXINGTON, Mass. , Oct. 14, 2020 / PRNewswire / -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a Trial in Progress abstract for CI-8993, a first-in-class monoclonal anti-VISTA antibody, has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 35 th Anniversary Annual Meeting, which will be held virtually from November 9-14, 2020 . Details of the poster session are as follows: Title: Phase 1 Study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies Author: Melissa L. Johnson , MD, Sarah Cannon Research Institute Date & Time: Wednesday, November 11 th , 2020 – Saturday, November 14 th , 2020 from 9:00 am – 5:00 pm ET Abstract ID: 743 Additional meeting information can be found on the SITC website at www.sitcancer.org . The poster presentation will also be available under "Events and Presentations" in the Investors section of the Company's website at www.curis.com About Curis, Inc. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/ 1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge ® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com . SOURCE Curis, Inc.

The release as fetched from its publisher. curis.com ↗